Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION 7: Zenagamtide vs Insulin Glargine in Type 2 Diabetes with Cardiovascular Risk
NCT07797335Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 16
01
Overview
A Phase 3 trial of amycretin in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07797335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797335.